title: [Serotonin syndrome during fluoxetine poisoning in a patient taking moclobemide].
abstract: OBJECTIVE
  To present a case of delayed serotonin syndome (SS), a less well-known adverse effect of fluoxetine intoxication.
  
  
  METHODS
  A 21-yr-old woman was admitted following voluntary intoxication with fluoxetine and benzodiazepines. At the time of admission, she was slightly drowsy and hypotonic but, eight hours later, she developed severe hypertonic coma despite blood concentrations of fluoxetine within the therapeutic range. Repeated toxicological analyses revealed the presence of moclobemide at non-measurable concentrations, suggesting earlier ingestion of this monoamine oxydase inhibitor. Having excluded all other likely causes of the neurological syndrome observed, a SS was postulated. Treatment was symptomatic with mechanical ventilation, sedation with thiopental and fentanyl, and neuromuscular block with pancuronium bromide. The patient recovered spontaneously 20 hr later.
  
  
  CONCLUSIONS
  Physicians managing patients presenting with fluoxetine intoxication must be aware of the potential risk of SS. Treatment is symptomatic, but SS may be severe and require vital support in the intensive care environment. Review of published reports does not allow the authors to recommend a specific anesthetic management.
authors.affiliation: Service de Réanimation, Centre Hospitalier de Villefranche sur Saône, France. mchamb@ch-villefranche.fr
authors.forename: M
authors.initials: M
authors.lastname: Chambost
authors.forename: L
authors.initials: L
authors.lastname: Liron
authors.forename: D
authors.initials: D
authors.lastname: Peillon
authors.forename: C
authors.initials: C
authors.lastname: Combe
mesh_terms: D000328:Adult; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D014151:Anti-Anxiety Agents / Q000506:poisoning; D000928:Antidepressive Agents / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000506:poisoning*; D001569:Benzodiazepines; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage; D005473:Fluoxetine / Q000506:poisoning*; D006801:Humans; D020912:Moclobemide / Q000009:adverse effects*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage; D010197:Pancuronium / Q000008:administration & dosage; D012121:Respiration, Artificial; D020230:Serotonin Syndrome / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000506:poisoning*; D013874:Thiopental / Q000008:administration & dosage
chemical_list: D018686:Anesthetics, Intravenous; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D001569:Benzodiazepines; D005283:Fentanyl; D005473:Fluoxetine; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D010197:Pancuronium; D017367:Selective Serotonin Reuptake Inhibitors; D013874:Thiopental